NCT02483884 - PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Prostate Cancer

Interventions

DRUG

[68Ga]RM2

\[68Ga\]RM2 is a novel 68Ga labeled, radiopharmaceutical agent for PET imaging. It is administered intravenously as a single dose of 140 MBq (corresponding to ≤ 40 μg mass dose)

PROCEDURE

PET/CT

Patients received \[68Ga\]RM2 undergo PET/CT 60 min p.i. for at least 20 min

Trial Locations (2)

4010

Krankenhaus der Barmherzigen Schwestern, Linz

20521

Turku PET Centre/Department of Oncology and Radiotherapy, Turku